Authors
Latest:
Is There a Role for Intralesional Therapy in Melanoma?On Monday during ASCO, Dr. Axel Hauschild reviewed the role of intralesional therapy in melanoma in a sub-session of the melanoma abstract review talk entitled “Evolving Utility of Intralesional Therapy for Melanoma.”
Latest:
Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL OutcomesAs part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.
Latest:
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side EffectsThis slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Latest:
Oncology Peer Review On-The-Go: Focus of Current and Emerging Therapies in Follicular LymphomaKirk E. Cahill, MD, and Sonali M. Smith, MD, spoke with CancerNetwork® about their review of the current management and treatment of follicular lymphoma published in the journal ONCOLOGY®.
Latest:
Combining Immune & Targeted Therapies in Melanoma: A Paradigm for Other Tumor Types?The story of how the targeted therapies, immunotherapies, and combinations of these therapies have been developed for use in patients with advanced melanoma holds a number of important lessons for the development of agents for use in other tumor types.
Latest:
ASCO 2016: Phase I Trial Results With Vorinostat in Head and Neck CancerIn this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
Latest:
Identifying and Treating Cytokine Release SyndromeWe spoke with Victoria Miller, FNP-BC, on how to identify and treat cytokine release syndrome in cancer patients being treated with immunotherapy at the Oncology Nursing Society 42nd Annual Congress, held May 4–7 in Denver.
Latest:
Venetoclax in the Context of the Current CLL Treatment ParadigmIn this podcast interview, Dr. William Wierda discusses the role of venetoclax in treating patients with chronic lymphocytic leukemia, particularly in light of recent trial results.
